These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 25049322)

  • 1. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
    Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
    J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
    Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    Brown JR; Hallek MJ; Pagel JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic lymphatic leukemia].
    Bergmann M; Wendtner CM
    Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P; Molik M; Foltynski P
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting Frontline Therapy for CLL in 2018.
    Jain N
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):242-247. PubMed ID: 30504317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
    Robak T; Burger JA; Tedeschi A; Barr PM; Owen C; Bairey O; Hillmen P; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre SE; Quach H; Gaidano G; Maslyak Z; Stevens DA; Moreno C; Gill DS; Flinn IW; Gribben JG; Mokatrin A; Cheng M; Styles L; James DF; Kipps TJ; Ghia P
    Am J Hematol; 2018 Nov; 93(11):1402-1410. PubMed ID: 30129285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
    Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
    Morabito F; Gentile M; Seymour JF; Polliack A
    Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
    Molica S
    Expert Rev Hematol; 2015 Jun; 8(3):277-81. PubMed ID: 25804936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
    Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
    Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current strategies to create tailored and risk-adapted therapies for CLL patients.
    Cramer P; Eichhorst B; Reinhardt HC; Hallek M
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
    Brown JR; O'Brien S; Kingsley CD; Eradat H; Pagel JM; Lymp J; Hirata J; Kipps TJ
    Blood; 2015 Apr; 125(18):2779-85. PubMed ID: 25769620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.